Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H27NO4 |
| Molecular Weight | 357.4434 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](O)COC[C@H](CC1=CC=C(O)C=C1)NC(=O)CCC2=CC=CC=C2
InChI
InChIKey=CDKPAWCGPQDCGU-LPHOPBHVSA-N
InChI=1S/C21H27NO4/c1-16(23)14-26-15-19(13-18-7-10-20(24)11-8-18)22-21(25)12-9-17-5-3-2-4-6-17/h2-8,10-11,16,19,23-24H,9,12-15H2,1H3,(H,22,25)/t16-,19-/m0/s1
| Molecular Formula | C21H27NO4 |
| Molecular Weight | 357.4434 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 07:15:32 GMT 2025
by
admin
on
Wed Apr 02 07:15:32 GMT 2025
|
| Record UNII |
470338M5XD
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
470338M5XD
Created by
admin on Wed Apr 02 07:15:32 GMT 2025 , Edited by admin on Wed Apr 02 07:15:32 GMT 2025
|
PRIMARY | |||
|
300000052509
Created by
admin on Wed Apr 02 07:15:32 GMT 2025 , Edited by admin on Wed Apr 02 07:15:32 GMT 2025
|
PRIMARY | |||
|
C211729
Created by
admin on Wed Apr 02 07:15:32 GMT 2025 , Edited by admin on Wed Apr 02 07:15:32 GMT 2025
|
PRIMARY | |||
|
13124
Created by
admin on Wed Apr 02 07:15:32 GMT 2025 , Edited by admin on Wed Apr 02 07:15:32 GMT 2025
|
PRIMARY | |||
|
51033894
Created by
admin on Wed Apr 02 07:15:32 GMT 2025 , Edited by admin on Wed Apr 02 07:15:32 GMT 2025
|
PRIMARY | |||
|
1443133-41-2
Created by
admin on Wed Apr 02 07:15:32 GMT 2025 , Edited by admin on Wed Apr 02 07:15:32 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
The exact mechanism of action of NRD135S.E1 is currently not elucidated. NRD135S.E1 does not appear to act directly through any of the mechanisms, receptors,
enzymes, or channels known to be associated with pain, including opioid receptors. Studies using U87 glioblastoma cells indicated that NRD135S.E1 may function indirectly through modifying Lyn kinase signaling
|